Cargando…
Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
Differentiated thyroid cancers (DTC) account for up to 85% of thyroid cancers and generally display an excellent prognosis. However, in a minority of cases, DTC progress toward less differentiated phenotypes leading to distant metastases and even disease-related deaths. Circulating biomarkers are wa...
Autores principales: | Giovanella, L., Imperiali, M., Trimboli, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544692/ https://www.ncbi.nlm.nih.gov/pubmed/28779086 http://dx.doi.org/10.1038/s41598-017-07915-0 |
Ejemplares similares
-
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020) -
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
por: Uenishi, T, et al.
Publicado: (2003) -
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
por: Xu, Youtao, et al.
Publicado: (2015) -
Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis
por: Jeong, Chaiho, et al.
Publicado: (2021) -
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2013)